Bing Yao, ArriVent Biopharma CEO

Ar­riVent prices $175M IPO in back-to-back on­col­o­gy biotech list­ings

Ar­riVent Bio­phar­ma will join the Nas­daq on Fri­day morn­ing in a strong start to biotech’s first batch of ini­tial pub­lic of­fer­ings this year.
The Penn­syl­va­nia …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.